Lyka Labs Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Lyka Labs.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump

Aug 22

Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now

Aug 03

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Jun 08

A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)

Mar 15

Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares

Aug 25

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

Jun 11

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Feb 21

Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are

Nov 05

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Nov 03

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Lyka Labs no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:LYKALABS - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	1,134	7	N/A	N/A	N/A
3/31/2024	1,062	-26	-75	18	N/A
12/31/2023	1,020	-37	N/A	N/A	N/A
9/30/2023	873	-159	-171	-68	N/A
6/30/2023	848	-158	N/A	N/A	N/A
3/31/2023	894	-133	8	90	N/A
12/31/2022	964	-254	N/A	N/A	N/A
9/30/2022	1,142	-89	193	217	N/A
6/30/2022	1,625	199	N/A	N/A	N/A
3/31/2022	1,845	389	717	792	N/A
12/31/2021	1,654	551	N/A	N/A	N/A
9/30/2021	1,567	467	633	703	N/A
6/30/2021	1,002	126	N/A	N/A	N/A
3/31/2021	685	-117	75	88	N/A
12/31/2020	723	-258	N/A	N/A	N/A
9/30/2020	638	-647	34	39	N/A
6/30/2020	648	-620	N/A	N/A	N/A
3/31/2020	567	-606	42	53	N/A
12/31/2019	731	-399	N/A	N/A	N/A
9/30/2019	723	-18	686	728	N/A
6/30/2019	714	-37	N/A	N/A	N/A
3/31/2019	671	-57	218	267	N/A
3/31/2018	604	-173	N/A	109	N/A
3/31/2017	994	-57	N/A	314	N/A
12/31/2016	1,503	-168	N/A	N/A	N/A
9/30/2016	1,491	-136	N/A	N/A	N/A
6/30/2016	1,476	-9	N/A	N/A	N/A
3/31/2016	1,782	53	N/A	159	N/A
12/31/2015	1,496	86	N/A	N/A	N/A
9/30/2015	1,572	22	N/A	N/A	N/A
6/30/2015	1,664	-51	N/A	265	N/A
6/30/2014	957	-43	N/A	713	N/A
12/31/2013	1,023	-232	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de LYKALABS es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de LYKALABS crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de LYKALABS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de LYKALABS crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de LYKALABS crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LYKALABS se prevé que sea elevada dentro de 3 años.

Lyka Labs Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Lyka Labs Limited Announces Resumption of Operations

Recent updates

Lyka Labs Limited to Report Q2, 2025 Results on Nov 12, 2024

There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump

New minor risk - Share price stability

Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now

Lyka Labs Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023)

Lyka Labs Limited, Annual General Meeting, Aug 09, 2024

Lyka Labs Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023)

Lyka Labs Limited to Report Q4, 2024 Results on May 21, 2024

Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹3.64 loss in 3Q 2023)

Lyka Labs Limited to Report Q3, 2024 Results on Feb 08, 2024

Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price

We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt

Second quarter 2024 earnings released: ₹0.16 loss per share (vs ₹0.14 loss in 2Q 2023)

Lyka Labs Limited to Report Q2, 2024 Results on Nov 02, 2023

Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w

Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director

Lyka Labs Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022)

Lyka Labs Limited, Annual General Meeting, Aug 02, 2023

Lyka Labs Limited, Annual General Meeting, Aug 02, 2023

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022)

Lyka Labs Limited to Report Q4, 2023 Results on May 23, 2023

A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)

Third quarter 2023 earnings released: ₹3.64 loss per share (vs ₹2.11 profit in 3Q 2022)

Lyka Labs Limited to Report Q3, 2023 Results on Feb 07, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: ₹0.14 loss per share (vs ₹9.90 profit in 2Q 2022)

Lyka Labs Limited to Report Q2, 2023 Results on Nov 09, 2022

High number of new directors

Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares

Investor sentiment improved over the past week

Lyka Labs Limited Announces Board Appointments

Lyka Labs Limited Announces Resignation of Smt. Nehal N. Gandhi as Director with Effect from August 8, 2022

Lyka Labs Limited Announces Cessation of Vinod S. Shanbhag as Independent Director

Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021)

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021)

Lyka Labs Limited, Annual General Meeting, Aug 05, 2022

Lyka Labs Limited to Report Q4, 2022 Results on May 20, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

High number of new directors

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Second quarter 2022 earnings released: EPS ₹9.90 (vs ₹2.01 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020)

Lyka Labs Limited Announces Information Regarding Manufacture and Market of Liposomal Amphotericin B Injection

Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.80 loss per share (vs ₹14.50 loss in 3Q 2020)

Lyka Labs Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day high: ₹25.60

Second quarter 2021 earnings released: ₹2.01 loss per share

Lyka Labs Limited Announces Resumption of Operations

First quarter earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura